● AI Equity Research · Healthcare

Aktis Oncology, Inc. (AKTS)

AI stock analysis · Biotechnology · Last analyzed Jul 8, 2026

Compass Score

4.0/5

Call

Buy

Price

$27.69

AI Target

$33.88 +22.4%

AI Analyst Summary

Aktis Oncology is an early-stage radiopharmaceutical biotech posting exceptional 123% YoY revenue growth, suggesting strong early commercial or clinical traction in a high-growth oncology niche. All 7 covering analysts rate the stock a Buy with a consensus target implying ~22% upside, reflecting confidence in the pipeline and platform differentiation. The primary risk is the company's loss-making status, negative forward P/E, and a very thin earnings history that leaves execution visibility limited.

Catalysts

Near-term clinical readouts from AKTS's radiopharmaceutical pipeline could serve as major re-rating events, with any Phase 2/3 data releases expected in upcoming quarters.
Continued acceleration of revenue growth beyond 123% YoY in Q2/Q3 results would validate commercial momentum and could trigger upward analyst price target revisions.
Potential partnership, licensing deal, or FDA regulatory milestone for its targeted alpha/beta therapy platform could unlock significant non-dilutive capital and market recognition.

Risks

Loss-making operations with a negative forward P/E of -14.3x create ongoing dilution risk; future equity raises could pressure share price if cash runway becomes a concern.
With only 1 quarter of EPS history and a miss recorded, execution consistency is unproven — a second miss or revenue deceleration could sharply erode analyst confidence.
The radiopharmaceutical space is increasingly competitive, with large-cap pharma entering the segment; failure to differentiate or secure commercial partnerships could limit long-term addressable market capture.

Fundamentals

Pe N/A (loss-making) · 1.0/5

Company is currently loss-making with no trailing P/E available and a negative forward P/E of -14.3x, typical for early-stage biotech but a clear valuation red flag.

Peg N/A · 3.0/5

PEG ratio is unavailable due to negative earnings. Defaulting to neutral score of 3, though the 123% revenue growth provides a constructive backdrop.

Analyst Rating Strong Buy consensus (1.0) · 5.0/5

All 7 analysts covering AKTS rate it a Buy with zero Hold or Sell ratings, representing a unanimously bullish consensus. Score capped at 5 given the clean sweep.

Earnings Trend Revenue +123% YoY; EPS N/A · 3.0/5

Revenue growth of 123% YoY is exceptional for an early-stage biotech, but the company remains unprofitable with no visible EPS trend. Strong top-line momentum partially offset by lack of earnings visibility.

Price Target Beat 0 of 1 quarters · 2.0/5

Only 1 quarter of EPS history available, with a miss recorded. Insufficient history to draw firm conclusions, but the lone data point is a miss, warranting a below-average score.

Management Limited track record · 3.0/5

Management is executing strongly on revenue growth (123% YoY), but the single-quarter EPS miss and early-stage status limit confidence. Unanimous analyst bullishness is a mild positive signal for capital allocation credibility.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.